Ruxolitinib treatment was well tolerated before and after allogeneic stem cell transplant (alloSCT) in a small retrospective analysis involving 15 individuals with myelofibrosis. Investigators looked at alloSCT outcomes in participants with myelofibrosis who—along with reduced intensity conditioning—received ruxolitinib before and after alloSCT (n=4), prior to alloSCT (n=7), or not at all (n=4). Among the results:
- Ruxolitinib was administered an average 8.3 months before and 12.5 months post-alloSCT.
- Average neutrophils engraft days for patients who received ruxolitinib before and after alloSCT was 13.3 days.
- The averages for those who received ruxolitinib before alloSCT or did not receive it were 13.6 and 16 days, respectively.
- Average spleen size reductions 6 months after alloSCT were 26%, 18%, and 18%, respectively.
- All patients were reported alive and in complete remission.
Poulose J, Malysz J, Claxton D, et al. Impact of ruxolitinib in myelofibrosis allogeneic stem cell transplant outcome: A pilot study. [Published online ahead of print December 7, 2017]. Blood. 130 (Suppl 1), 5543.
This Week's Must Reads
Global Burden of CVD in People Living with HIV, Circulation; ePub 2018 Jul 2; Shah, et al
Penicillin Allergy & Risk of MRSA and C. difficle, BMJ; ePub 2018 Jun 27; Blumenthal, et al
Does Sleep Debt Decrease with Age? , Sleep Health; ePub 2018 Jun 28; Fox, et al
Firearm Injuries in Children & Adolescents, Pediatrics; ePub 2018 Jul 2; Herrin, et al
Effects of Pulse Pressure & BP Tx Intensity on AEs, Am J Med; ePub 2018 Jun 22; Krishnaswami, et al
Must Reads in Hematologic Malignancies
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al
Tyrosine Kinase Inhibitors in Pediatric ALL, Hematology 2017; 2017 Dec 8; Silverman, et al